Nymox Pharmaceutical Corp (NYMXF) Common Stock USD NPV

Sell:$0.09Buy:$0.09No change

Prices delayed by at least 15 minutes
Sell:$0.09
Buy:$0.09
Change:No change
Prices delayed by at least 15 minutes
Sell:$0.09
Buy:$0.09
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NYMOZARFEX, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company also has a patent portfolio covering its marketed products, its investigational drug as well as other therapeutic and diagnostic indications. It also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. Its products also include NicAlert and TobacAlert. NicAlert is a simple test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample. TobacAlert is a home test that provides a quick, accurate, on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke.

Key people

Paul Averback
Chairman of the Board, President, Chief Executive Officer
Patrick Doody
Vice President, General Counsel, Director
David Morse
Independent Director
James G. Robinson
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    BSP733981026
  • Market cap
    $8.41m
  • Employees
    3
  • Shares in issue
    93.45m
  • Exchange
    Over The Counter
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.